BackShanghai Hile Bio-Technology , Ltd. Overview

Shanghai Hile Bio-Technology , Ltd. Receivables

Track Shanghai Hile Bio-Technology , Ltd.'s receivables ($160M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$158.98M
↑ 37.40% YoYΔ $43.28M vs prior year quarter

Peer trimmed avg / median

Loading

Shanghai Hile Bio-Technology , Ltd. Receivables History

Loading

Shanghai Hile Bio-Technology , Ltd. vs. peers: Receivables Comparison

Loading

Shanghai Hile Bio-Technology , Ltd. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Shanghai Hile Bio-Technology , Ltd. (603718.SS) FAQ

As of the most recent data (September 2026), 603718.SS shows a receivables of $160M. That compares with $120M in the prior-year period — up 37.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 603718.SS's receivables is now $160M (was $120M) — a 37.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Shanghai Hile Bio-Technology , Ltd. is outperforming or lagging.

Tracking 603718.SS's receivables over time shows whether Shanghai Hile Bio-Technology , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $160M That compares with $120M in the prior-year period — up 37.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Shanghai Hile Bio-Technology , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $160M) with ownership activity and broader fundamentals.

Shanghai Hile Bio-Technology , Ltd.'s receivables is $160M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.